Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Cambridge, Massachusetts
- Most recent report
- 8-K/A, filed Aug 14, 2026
- Filings on record
- 34 filings
- On EDGAR
- CIK 2130606
- Fiscal year ends
- December
- Filer status
- Non-accelerated filer, Emerging growth company
Financials 1
News 2
Prospectuses and Registrations 8
- S-1 Registration statement for an offering Aug 28, 2026
- S-8 Registration statement for an employee plan Aug 3, 2026
- 424B3 Prospectus supplement for an offering Jul 2, 2026
- S-4/A Registration statement for a merger or exchange, amended Jul 2, 2026
- S-4/A Registration statement for a merger or exchange, amended Jun 30, 2026
- S-4/A Registration statement for a merger or exchange, amended Jun 24, 2026
- S-4/A Registration statement for a merger or exchange, amended Jun 2, 2026
- S-4 Registration statement for a merger or exchange Apr 22, 2026
Ownership 8 of 18
- SCHEDULE 13G Large holder reported a passive stake Aug 11, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 10, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 10, 2026
- SCHEDULE 13G Large holder reported a passive stake Aug 10, 2026
- 4 Insider reported a trade Aug 5, 2026
- 4 Insider reported a trade Aug 5, 2026
- 4 Insider reported a trade Aug 5, 2026
- 4 Insider reported a trade Aug 5, 2026
Other 5
- EFFECT Notice that a registration became effective Sep 9, 2026
- CERT Exchange certified a listing Aug 3, 2026
- 8-A12B/A Registration of a security for exchange listing, amended Aug 3, 2026
- 8-A12B Registration of a security for exchange listing Aug 3, 2026
- EFFECT Notice that a registration became effective Jul 2, 2026
Everything here comes from Obsidian Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.